Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
8.21
+0.65 (8.60%)
Aug 13, 2025, 4:00 PM - Market closed
Gyre Therapeutics Revenue
Gyre Therapeutics had revenue of $26.77M in the quarter ending June 30, 2025, with 6.13% growth. This brings the company's revenue in the last twelve months to $102.19M, down -8.42% year-over-year. In the year 2024, Gyre Therapeutics had annual revenue of $105.76M, down -6.78%.
Revenue (ttm)
$102.19M
Revenue Growth
-8.42%
P/S Ratio
6.95
Revenue / Employee
$176,492
Employees
579
Market Cap
745.66M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 105.76M | -7.69M | -6.78% |
Dec 31, 2023 | 113.45M | 11.16M | 10.91% |
Dec 31, 2022 | 102.29M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionGYRE News
- 2 days ago - Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update - GlobeNewsWire
- 2 months ago - Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China - GlobeNewsWire
- 2 months ago - Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 2 months ago - Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock - GlobeNewsWire
- 2 months ago - Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock - GlobeNewsWire
- 2 months ago - Gyre Therapeutics' Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China - GlobeNewsWire
- 3 months ago - Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications - GlobeNewsWire